SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceuticals has hit out at the proposed draft new pharma pricing policy (NPPP), 2011, which can lead to shortage of drugs and severely hurt the interests of domestic industry and patients.

The draft policy only looks in terms of price reduction, which is a short-term approach and neither addresses the needs of the industry nor those of patients. The draft NPPP, 2011 intends to bring 60% of the total domestic pharmaceutical market amounting to nearly Rs 29,000 crore under price control by bringing all the 348 drugs specified in the National List of Essential Medicines 2011 under price control. 

Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×